Currently, the PD-1-PD-L1 immune-checkpoint (IC) is taking a great relevance as a target for immunotherapy in a large number of cancers, since blocking this pathway leads to antitumor responses with the consequent clinical benefit for some patients. The gene discussed is PDCD1; the disease is cancer.